Literature DB >> 30016236

Direct Detection of penA Gene Associated with Ceftriaxone-Resistant Neisseria gonorrhoeae FC428 Strain by Using PCR.

David M Whiley, Lebogang Mhango, Amy V Jennison, Graeme Nimmo, Monica M Lahra.   

Abstract

The ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone was first observed in Japan in 2015, and in 2017, it was documented in Denmark, Canada, and Australia. Here, we describe a PCR for direct detection of the penA gene associated with this strain that can be used to enhance surveillance activities.

Entities:  

Keywords:  Australia; Canada; Denmark; FC428 clone; Japan; N. lactamica; N. meningitides; Neisseria gonorrhoeae; PBP2; antimicrobial resistance; ceftriaxone; oligonucleotide; penA; penicillin-binding protein 2

Mesh:

Substances:

Year:  2018        PMID: 30016236      PMCID: PMC6056102          DOI: 10.3201/eid2408.180295

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Ceftriaxone, either monotherapy or in dual therapy with azithromycin, is the mainstay of treatment of patients diagnosed with Neisseria gonorrhoeae infection in most settings (). Therefore, the identification of any strains exhibiting resistance to ceftriaxone is of considerable public health concern. Until 2017, ceftriaxone-resistant strains of N. gonorrhoeae had been rare and typically sporadic, including in 2009, H041 in Japan (); in 2010, F89 in France (); in 2011, F89 in Spain (); in 2013, A8806 in Australia (); in 2014, GU140106 in Japan (); and in 2015, FC428 and FC460 in Japan (). However, there is now evidence of sustained international transmission of FC428, reported during 2017 in Canada () and Demark () (1 case each) and in Australia (2 cases) (). Rapid and timely detection is pivotal to contain further spread of antimicrobial drug–resistant N. gonorrhoeae. Here, we describe a real-time PCR protocol to facilitate enhanced surveillance for the FC428 clone. The study was approved by the University of Queensland Human Research Ethics Committee.

The Study

We designed a real-time PCR to target unique sequences on the penA gene of the FC428 N. gonorrhoeae clone (). Modifications of penA, which encodes penicillin-binding protein 2 (PBP2), are a cause of cephalosporin resistance in N. gonorrhoeae. The FC428 clone harbors a mosaic penA-allele, designated as PenA-60.001 by results of N. gonorrhoeae sequence typing for antimicrobial drug resistance (), and encodes alterations including A311V and T483S that have previously been associated with N. gonorrhoeae ceftriaxone resistance in H041 () and A8806 (,) strains. For this study, we designed 2 primers and 2 allele-specific probes (Table 1) to facilitate specific detection of the penA gene of FC428. In brief, the forward and reverse primers were designed to flank the A311V alteration; probe 1 was designed for detection of the A311V alteration; and probe 2 was designed to detect the wild-type A311 sequence. We added probe 2 to act as a blocker probe to limit binding of probe 1 with the wild-type sequence.
Table 1

Primer and probe sequences for PCR to detect Neisseria gonorrhoeae FC428 strain*

DesignationOligonucleotide sequence, 5′ → 3′
Forward primerCGCAACCGTGCCGTT
Reverse primerGGGTATTGAATGTGTCTGTTGGA
Probe 1Fam-TTCA+T+G+A+CA+G+AAC-Iowa Black FQ
Probe 2Hex-TCA+T+G+G+CA+GA-Iowa Black FQ

*LNA bases are indicated by + preceding the base in the sequence.

*LNA bases are indicated by + preceding the base in the sequence. We prepared the reaction mix by using the QuantiTect Probe PCR Master Mix Kit (QIAGEN, Doncaster, Victoria, Australia). The reaction consisted of 12.5 µL of the Master Mix, 10 pmol/L of forward and reverse primers (Table 1), 4.0 pmol/L of each probe, and 5.0 µL of specimen nucleic acid, resulting in a total volume of 25 µL. We thermocycled the reaction mix by using the Rotor-Gene 6000 instrument (QIAGEN) and held it at 95°C for 15 min, then cycled (45 cycles) at 95°C for 15 s and 60°C for 60 s. We analyzed data by using the Rotor-Gene allelic discrimination software (QIAGEN). We initially assessed the analytical performance of the assay by testing cultured isolates of N. gonorrhoeae (n = 72) and commensal Neisseria and Moraxella species (n = 111) (Table 2). We prepared these isolates by using a previously described heat-denaturation method (). The N. gonorrhoeae isolates included the 2 FC428 strains recently documented in Australia (), H041 () and A8806 (); the ceftriaxone-resistant strains; and other local clinical N. gonorrhoeae isolates (n = 68). Both FC428 isolates provided strong positive signals by using probe 1 with cycle threshold (Ct) values <20 cycles. The A8806 strain provided a late reaction at 37.8 cycles (probe 1), as did 2 commensal Neisseria strains: 1 N. lactamica isolate at 42.8 cycles for (probe 1), and 1 N. meningitidis isolate at 32.6 cycles (probe 2). The Figure shows a sequence alignment of the partial penA sequences from these 3 isolates compared with the FC428 PenA-60.001 allele. The A8806 strain shows considerable sequence homology with PenA-60.001 (including 100% match with the A311V Probe 1 sequence), albeit for 2 mutations in the forward primer designed to limit detection of A8806. We do not consider this a limitation of the assay because there has only been 1 reported case of infection with the A8806 strain. Neither the N. lactamica or N. meningitidis isolates harbored the A311V alteration.
Table 2

Neisseria spp. isolates and specimens tested in development of PCR to detect Neisseria gonorrhoeae FC428 strain*

Isolates/samples
PCR results for FC428 (Ct)
Probe 1
Probe 2
Gonococcal species, n = 144
Neisseria gonorrhoeae, n = 72
N. gonorrhoeae FC428, n = 2 (9)†Positive (19.8 and 18.17 cycles)Negative
N. gonorrhoeae H041, n = 1 (1)NegativeNegative
N. gonorrhoeae A8806, n = 1 (4)Positive (37. 8 cycles)Negative
N. gonorrhoeae, n = 68‡
Negative
Negative
Nongonococcal species, n = 111
N. cinerea, n = 4NegativeNegative
N. elongata, n = 1NegativeNegative
N. flavescens, n = 1NegativeNegative
N. lactamica, n = 15NegativeNegative
N. lactamica, n = 1Positive (42.8 cycles)Negative
N. meningitidis, n = 55NegativeNegative
N. meningitidis, n = 1NegativePositive (32.6 cycles)
N. mucosa, n = 1NegativeNegative
N. polysacchareae, n = 4NegativeNegative
N. sicca, n = 4NegativeNegative
N. subflava, n = 14NegativeNegative
N. weaveri, n = 1NegativeNegative
Moraxella catarrhalis, n = 7NegativeNegative
M. osloensis, n = 2
Negative
Negative
N. gonorrhoeae NAAT-positive clinical specimens, n = 358
Urogenital, n = 172NegativeNegative
Anal swab, n = 81NegativeNegative
Throat swab, n = 95NegativeNegative
Other, n = 10NegativeNegative

*Ct, cycle threshold; NAAT, nucleic acid amplification test.
†Isolates A7846 and A7536.
‡Other local clinical isolates collected in New South Wales, Australia.

Figure

Sequence alignment showing the expected 112-bp PCR product for the PCR to detect Neisseria gonorrhoeae FC428 strain. PenA type 60.001 is provided as the reference sequence. Gray indicates the primer targets and the 311 codon within the probe target sequences. The penA sequences from the N. gonorrhoeae A8806, N. meningitidis, and N. lactamica isolates that cross-reacted with the FC428 PCR are also provided. Dots indicate sequence identity.

*Ct, cycle threshold; NAAT, nucleic acid amplification test.
†Isolates A7846 and A7536.
‡Other local clinical isolates collected in New South Wales, Australia. Sequence alignment showing the expected 112-bp PCR product for the PCR to detect Neisseria gonorrhoeae FC428 strain. PenA type 60.001 is provided as the reference sequence. Gray indicates the primer targets and the 311 codon within the probe target sequences. The penA sequences from the N. gonorrhoeae A8806, N. meningitidis, and N. lactamica isolates that cross-reacted with the FC428 PCR are also provided. Dots indicate sequence identity. To compare detection limits, we tested 10-fold dilutions of FC428 DNA by both the FC428 PCR and a previously described in-house N. gonorrhoeae PCR, directed at the gonococcal porA and opa sequences (). The in-house N. gonorrhoeae PCR had the lowest detection limit at 0.3 genome copies/reaction, whereas the detection limit of the FC428 PCR was 3.0 genome copies/reaction, indicating the FC428 PCR was 1 log less sensitive than the diagnostic method. We then applied the assay to a convenience panel of N. gonorrhoeae–positive clinical samples (n = 358) submitted to Pathology Queensland Laboratory (Brisbane, Queensland, Australia) during February–September 2017 (Table 2). In brief, these samples comprised remnant nucleic acids from samples that tested positive for N. gonorrhoeae by the Cobas 4800 CT/NG test and were confirmed positive by using the in-house N. gonorrhoeae PCR (). All samples provided negative results by the FC428 PCR, suggesting that the FC428 strain was not present in Queensland during this period.

Conclusions

Overall, our results suggest that the FC428 PCR is suitable for screening for the FC428 N. gonorrhoeae clone in clinical specimens for which culture is not available. The method could prove to be a strategic tool to enhance surveillance if FC428 continues to spread. We recommend that positive results be confirmed by, for example, DNA sequencing, particularly if the strain is detected in a pharyngeal sample in which other commensal Neisseria species are prevalent.
  12 in total

1.  A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia.

Authors:  Monica M Lahra; Nathan Ryder; David M Whiley
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

Review 2.  Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium.

Authors:  Magnus Unemo; Jorgen S Jensen
Journal:  Nat Rev Urol       Date:  2017-01-10       Impact factor: 14.432

3.  Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.

Authors:  Makoto Ohnishi; Daniel Golparian; Ken Shimuta; Takeshi Saika; Shinji Hoshina; Kazuhiro Iwasaku; Shu-ichi Nakayama; Jo Kitawaki; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

4.  High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.

Authors:  Magnus Unemo; Daniel Golparian; Robert Nicholas; Makoto Ohnishi; Anne Gallay; Patrice Sednaoui
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

5.  New Ceftriaxone- and Multidrug-Resistant Neisseria gonorrhoeae Strain with a Novel Mosaic penA Gene Isolated in Japan.

Authors:  Shu-Ichi Nakayama; Ken Shimuta; Kei-Ichi Furubayashi; Takuya Kawahata; Magnus Unemo; Makoto Ohnishi
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

6.  Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain.

Authors:  Jordi Cámara; Judit Serra; Josefina Ayats; Teresa Bastida; Dolors Carnicer-Pont; Antònia Andreu; Carmen Ardanuy
Journal:  J Antimicrob Chemother       Date:  2012-05-07       Impact factor: 5.790

7.  A duplex Neisseria gonorrhoeae real-time polymerase chain reaction assay targeting the gonococcal porA pseudogene and multicopy opa genes.

Authors:  Namraj Goire; Michael D Nissen; Genevera M LeCornec; Theo P Sloots; David M Whiley
Journal:  Diagn Microbiol Infect Dis       Date:  2008-01-14       Impact factor: 2.803

8.  Simple, rapid, and inexpensive detection of Neisseria gonorrhoeae resistance mechanisms using heat-denatured isolates and SYBR green-based real-time PCR.

Authors:  Gayle Kugelman; John W Tapsall; Namraj Goire; Melanie W Syrmis; Athena Limnios; Stephen B Lambert; Michael D Nissen; Theo P Sloots; David M Whiley
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

9.  New Clinical Strain of Neisseria gonorrhoeae with Decreased Susceptibility to Ceftriaxone, Japan.

Authors:  Takashi Deguchi; Mitsuru Yasuda; Kyoko Hatazaki; Koji Kameyama; Kengo Horie; Taku Kato; Kohsuke Mizutani; Kensaku Seike; Tomohiro Tsuchiya; Shigeaki Yokoi; Masahiro Nakano; Mutsumasa Yoh
Journal:  Emerg Infect Dis       Date:  2016-01       Impact factor: 6.883

10.  Ceftriaxone-Resistant Neisseria gonorrhoeae, Canada, 2017.

Authors:  Brigitte Lefebvre; Irene Martin; Walter Demczuk; Lucie Deshaies; Stéphanie Michaud; Annie-Claude Labbé; Marie-Claude Beaudoin; Jean Longtin
Journal:  Emerg Infect Dis       Date:  2018-02-17       Impact factor: 6.883

View more
  7 in total

Review 1.  World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts.

Authors:  Magnus Unemo; Monica M Lahra; Michelle Cole; Patricia Galarza; Francis Ndowa; Irene Martin; Jo-Anne R Dillon; Pilar Ramon-Pardo; Gail Bolan; Teodora Wi
Journal:  Sex Health       Date:  2019-09       Impact factor: 2.706

2.  Typing of Neisseria Gonorrhoeae isolates in Shenzhen, China from 2014-2018 reveals the shift of genotypes associated with antimicrobial resistance.

Authors:  Yizhun Li; Yamei Li; Leshan Xiu; Yaling Zeng; Chi Zhang; Liying Sun; LuLu Zhang; Feng Wang; Junping Peng
Journal:  Antimicrob Agents Chemother       Date:  2021-02-16       Impact factor: 5.191

3.  A Loop-Mediated Isothermal Amplification Assay Targeting Neisseria gonorrhoeae penA-60.001.

Authors:  Ken Shimuta; Shu-Ichi Nakayama; Hideyuki Takahashi; Makoto Ohnishi
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

Review 4.  Bridging the gap between development of point-of-care nucleic acid testing and patient care for sexually transmitted infections.

Authors:  Kuangwen Hsieh; Johan H Melendez; Charlotte A Gaydos; Tza-Huei Wang
Journal:  Lab Chip       Date:  2022-02-01       Impact factor: 7.517

5.  Genetic relatedness of ceftriaxone-resistant and high-level azithromycin resistant Neisseria gonorrhoeae cases, United Kingdom and Australia, February to April 2018.

Authors:  Amy V Jennison; David Whiley; Monica M Lahra; Rikki M Graham; Michelle J Cole; Gwenda Hughes; Helen Fifer; Monique Andersson; Anne Edwards; David Eyre
Journal:  Euro Surveill       Date:  2019-02

6.  Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018.

Authors:  David W Eyre; Katy Town; Teresa Street; Leanne Barker; Nicholas Sanderson; Michelle J Cole; Hamish Mohammed; Rachel Pitt; Maya Gobin; Charles Irish; Daniel Gardiner; James Sedgwick; Charles Beck; John Saunders; Deborah Turbitt; Clare Cook; Nick Phin; Bavithra Nathan; Paddy Horner; Helen Fifer
Journal:  Euro Surveill       Date:  2019-03

7.  Genetic Characterization and Enhanced Surveillance of Ceftriaxone-Resistant Neisseria gonorrhoeae Strain, Alberta, Canada, 2018.

Authors:  Byron M Berenger; Walter Demczuk; Jennifer Gratrix; Kanti Pabbaraju; Petra Smyczek; Irene Martin
Journal:  Emerg Infect Dis       Date:  2019-09-17       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.